Secondary outcomes were change in liver histology ( @ control and @ ezetimibe patients ) , insulin sensitivity including a hyperinsulinaemic-euglycaemic clamp study ( ten control and @ ezetimibe patients ) and hepatic fatty acid composition ( six control and nine ezetimibe patients ) .